Gujarat Themis Biosyn Ltd
GUJTHEM
Company Profile
Business description
Gujarat Themis Biosyn Ltd is engaged in manufacturing, exporting, and selling of bulk drugs on a job-work basis. The company operates in one segment which is pharmaceuticals. Its products include Rifamycin-S, which is an intermediate for Rifampicin for the treatment of tuberculosis (TB), and Lovastatin.
Contact
S.V Road
Themis House, 11/12 Udyog Nagar
Goregaon (West)
MumbaiMH400104
INDT: +91 2267607080
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2025
Employees
265
Stocks News & Analysis
stocks
Potential moonshot investment at ASX tech leader
Investors may be over optimistic about the prospects for a new revenue source.
stocks
These ASX earnings season dogs may have fallen too far
The longer term outlook for these moated companies looks far brighter than markets seem to be giving them credit for.
stocks
Our view of the supermarkets after earnings
Are the shares of two of Australia’s best known brands attractive?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,478.80 | 74.90 | 0.89% |
| CAC 40 | 8,199.71 | 88.08 | 1.09% |
| DAX 40 | 23,147.02 | 595.59 | 2.64% |
| Dow JONES (US) | 43,398.06 | 442.85 | -1.01% |
| FTSE 100 | 8,871.31 | 61.57 | 0.70% |
| HKSE | 23,006.27 | 64.95 | 0.28% |
| NASDAQ | 18,536.82 | 310.46 | -1.65% |
| Nikkei 225 | 37,785.47 | 629.97 | 1.70% |
| NZX 50 Index | 12,550.05 | 51.37 | -0.41% |
| S&P 500 | 5,887.92 | 66.58 | -1.12% |
| S&P/ASX 200 | 8,245.70 | 73.30 | 0.90% |
| SSE Composite Index | 3,316.93 | 3.97 | -0.12% |